RxDoctor Payments Data

Timothy Hernandez, MD

Internal Medicine · San Antonio, TXNPI 1851495584

Payments from drug & device makers

$669in general payments, 2019–2025

Across 22 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$125
  • Abbott$125
  • Boehringer Ingelheim$123
  • Amgen$93
  • AbbVie$61
  • Pfizer$36
  • plus $106 from 5 others

What the payments were for

  • Food & beverage$669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$669 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$150,813
Medicare patients
304
Services billed
3,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide183$223,836
FarxigaDapagliflozin Propanediol127$138,453
OzempicSemaglutide86$90,605
TrulicityDulaglutide61$82,392
EliquisApixaban70$79,952
JardianceEmpagliflozin53$55,534
InvokanaCanagliflozin17$22,629
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,603
MyrbetriqMirabegron14$11,604
PaxlovidNirmatrelvir/Ritonavir51$9,886
TradjentaLinagliptin15$9,778
XyostedTestosterone Enanthate12$6,762
Rosuvastatin Calcium404$5,094
CreonLipase/Protease/Amylase13$3,925
SynthroidLevothyroxine Sodium41$3,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$90,60586 claims
PfizerEliquis, Paxlovid$36$89,838121 claims
Boehringer IngelheimJardiance, Tradjenta$123$65,31268 claims
Johnson & JohnsonInvokana$13$22,62917 claims
GSKTrelegy Ellipta$33$22,60321 claims
AbbVieCreon, Synthroid$61$7,08254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →